Bristol Myers Squibb controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2021
Bristol Myers Squibb sues Eugia Pharma over Sprycel patents
Lawsuit filed
Bristol Myers Squibb filed a lawsuit against Eugia Pharma Specialties alleging that Eugia submitted an application to market a generic equivalent of Sprycel before the relevant patents expired. Bristol Myers Squibb seeks injunctive relief and monetary damages.
Source excerpt
The plaintiff accuses Eugia Phama of submitting a ANDA to offer a generic equivalent for Sprycel prior to the expiration of the involved patents.
On Wednesday a case was filed in the District of New Jersey. The case was filed by Bristol Myers Squibb Company against Eugia Pharma Specialties.
2020
China suspends imports, sales and use of Bristol Myers Squibb paclitaxel product
Ban or restriction
In March 2020, China's National Medical Products Administration announced the suspension of imports, sales and use of Bristol Myers Squibb's albumin-bound paclitaxel product. The agency said the action was based on inspection findings at a U.S. contract manufacturing facility. The announcement identified the product as albumin-bound paclitaxel and described the measure as a suspension covering import, sale and use in China. The notice did not specify further details beyond the inspection findings at the contract manufacturing site as the basis for the decision.
Source excerpt
公司于3月25日获悉，国家药品监督管理局宣布暂停进口、销售和使用美国新基公司(现隶属百时美施贵宝)注射用紫杉醇(白蛋白结合型)产品的决定。此项决定是基于对百时美施贵宝一家位于美国的合同生产机构的核查结果做出的。
2006
Plavix distribution and channel-stuffing controversy
The FBI searched BMS corporate offices in connection with allegations involving Plavix distribution, channel stuffing, and generic competition. A court-appointed monitor urged removal of CEO Peter Dolan, who stepped down. The deferred-prosecution agreement ended in 2007 without further Department of Justice action on the matters covered by it.